RITUXAN (rituximab) is no longer covered on the Reformulary. Reformulary covers a specific rituximab biosimilar: RIXIMYO, manufactured by Sandoz, a division of Novartis Canada. RIXIMYO is considered a preferred rituximab biosimilar as it offers the same clinical value at a lower net cost to the plan. RIXIMYO requires Special Authorization.
Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.